The Australian reports that their Therapeutic Goods Administration (TGA) received new data from drug company Janssen-Cilag, the developers of risperidone, “indicating a more than fivefold higher risk of ‘cerebrovascular adverse events’ — stroke or transient ischaemic attack — in patients with vascular or mixed dementia on risperidone.”